[Back to Our Trials]
Relativity-123: A Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Go To Trial Homepage
For more information you may call clinical trials department directly at 732-390-7750 or email us at
astera.clinicaltrial@asterahealthcare.org
.